95 related articles for article (PubMed ID: 10048954)
1. Metabolic and receptor imaging of metastatic medullary thyroid cancer: does anti-CEA and somatostatin-receptor scintigraphy allow for prognostic predictions?
Behr TM; Becker W
Eur J Nucl Med; 1999 Jan; 26(1):70-1. PubMed ID: 10048954
[No Abstract] [Full Text] [Related]
2. Anti-carcinoembryonic antigen antibodies versus somatostatin analogs in the detection of metastatic medullary thyroid carcinoma: are carcinoembryonic antigen and somatostatin receptor expression prognostic factors?
Behr TM; Gratz S; Markus PM; Dunn RM; Hüfner M; Schauer A; Fischer M; Munz DL; Becker H; Becker W
Cancer; 1997 Dec; 80(12 Suppl):2436-57. PubMed ID: 9406695
[TBL] [Abstract][Full Text] [Related]
3. [Somatostatin receptor scintigraphy in medullary thyroid carcinomas, GEP and carcinoid tumors].
Eising EG; Farahati J; Bier D; Knust EJ; Reiners C
Nuklearmedizin; 1995 Feb; 34(1):1-7. PubMed ID: 7724358
[TBL] [Abstract][Full Text] [Related]
4. Somatostatin and somatostatin analogues in medullary thyroid carcinoma.
O'Byrne KJ; O'Hare N; Sweeney E; Freyne PJ; Cullen MJ
Nucl Med Commun; 1996 Sep; 17(9):810-6. PubMed ID: 8895910
[TBL] [Abstract][Full Text] [Related]
5. Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma.
Baudin E; Lumbroso J; Schlumberger M; Leclere J; Giammarile F; Gardet P; Roche A; Travagli JP; Parmentier C
J Nucl Med; 1996 Jun; 37(6):912-6. PubMed ID: 8683310
[TBL] [Abstract][Full Text] [Related]
6. Enhanced bilateral somatostatin receptor expression in mediastinal lymph nodes ("chimney sign") in occult metastatic medullary thyroid cancer: a typical site of tumour manifestation?
Behr TM; Gratz S; Markus PM; Dunn RM; Hüfner M; Becker H; Becker W
Eur J Nucl Med; 1997 Feb; 24(2):184-91. PubMed ID: 9021116
[TBL] [Abstract][Full Text] [Related]
7. The contribution of somatostatin receptor scintigraphy to the diagnosis of recurrent medullary carcinoma of the thyroid.
Dörr U; Sautter-Bihl ML; Bihl H
Semin Oncol; 1994 Oct; 21(5 Suppl 13):42-5. PubMed ID: 7992080
[No Abstract] [Full Text] [Related]
8. 111In-octreotide scintigraphy in metastatic medullary thyroid carcinoma before and after octreotide therapy: in vivo evidence of the possible down-regulation of somatostatin receptors.
Ronga G; Salerno G; Procaccini E; Mauro L; Annovazzi A; Barone R; Mellozzi M; Tamburrano G; Signore A
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):134-6. PubMed ID: 9002772
[TBL] [Abstract][Full Text] [Related]
9. Somatostatin receptor scintigraphy for early detection of regional and distant metastases of medullary carcinoma of the thyroid.
Krausz Y; Rosler A; Guttmann H; Ish-Shalom S; Shibley N; Chisin R; Glaser B
Clin Nucl Med; 1999 Apr; 24(4):256-60. PubMed ID: 10466522
[TBL] [Abstract][Full Text] [Related]
10. Somatostatin receptor imaging in persistent medullary thyroid carcinoma.
Frank-Raue K; Bihl H; Dörr U; Buhr H; Ziegler R; Raue F
Clin Endocrinol (Oxf); 1995 Jan; 42(1):31-7. PubMed ID: 7889629
[TBL] [Abstract][Full Text] [Related]
11. Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA x anti-DTPA-indium bispecific antibody.
Barbet J; Peltier P; Bardet S; Vuillez JP; Bachelot I; Denet S; Olivier P; Leccia F; Corcuff B; Huglo D; Proye C; Rouvier E; Meyer P; Chatal JF
J Nucl Med; 1998 Jul; 39(7):1172-8. PubMed ID: 9669389
[TBL] [Abstract][Full Text] [Related]
12. 111In-octreotide scintigraphy in endocrine tumors. Preliminary data.
Cremonini N; Furno A; Sforza A; Chiarini V; Graziano E; Zampa G; Turba E
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):116-20. PubMed ID: 9002767
[TBL] [Abstract][Full Text] [Related]
13. Indium-111-DTPA-D-Phe-1-octreotide and technetium-99m-(V)-dimercaptosuccinic acid scanning in the preoperative staging of medullary thyroid carcinoma.
Kurtaran A; Scheuba C; Kaserer K; Schima W; Czerny C; Angelberger P; Niederle B; Virgolini I
J Nucl Med; 1998 Nov; 39(11):1907-9. PubMed ID: 9829581
[TBL] [Abstract][Full Text] [Related]
14. Detection of cervical metastases of thyroid medullary carcinoma by MoAb anti-CEA scintigraphy and immunohistochemistry.
Parkkila S; Ahonen A; Torniainen P; Heikkilä J; Salmela P
Eur J Nucl Med; 1995 Sep; 22(9):1064-8. PubMed ID: 7588944
[TBL] [Abstract][Full Text] [Related]
15. Successful surgical removal of occult metastases of medullary thyroid carcinoma recurrences with the help of immunoscintigraphy and radioimmunoguided surgery.
de Labriolle-Vaylet C; Cattan P; Sarfati E; Wioland M; Billotey C; Brochériou C; Rouvier E; de Roquancourt A; Rostène W; Askienazy S; Barbet J; Milhaud G; Gruaz-Guyon A
Clin Cancer Res; 2000 Feb; 6(2):363-71. PubMed ID: 10690512
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of somatostatin receptor scintigraphy.
Kwekkeboom DJ; Lamberts SW; Habbema JD; Krenning EP
J Nucl Med; 1996 Jun; 37(6):886-92. PubMed ID: 8683305
[TBL] [Abstract][Full Text] [Related]
17. [Somatostatin receptor scintigraphy. Methodology, indications, results].
Eising EG; Bier D; Knust EJ; Reiners C
Radiologe; 1996 Jan; 36(1):81-8. PubMed ID: 8820376
[TBL] [Abstract][Full Text] [Related]
18. Somatostatin-receptor imaging of medullary thyroid carcinoma.
Krausz Y; Ish-Shalom S; Dejong RB; Shibley N; Lapidot M; Maaravi Y; Glaser B
Clin Nucl Med; 1994 May; 19(5):416-21. PubMed ID: 7913671
[TBL] [Abstract][Full Text] [Related]
19. [Accumulation of radioactivity in the lung after 111In-octreotide scintigraphy].
Schleicher UM; Cremerius U; Schubert H
Rofo; 1998 Apr; 168(4):404-6. PubMed ID: 9589108
[No Abstract] [Full Text] [Related]
20. In vivo somatostatin receptor imaging in medullary thyroid carcinoma.
Kwekkeboom DJ; Reubi JC; Lamberts SW; Bruining HA; Mulder AH; Oei HY; Krenning EP
J Clin Endocrinol Metab; 1993 Jun; 76(6):1413-7. PubMed ID: 8501144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
